You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Life & Medical Care

Global Chronic Idiopathic Constipation Drugs Market Study 2016-2026, by Segment (Linaclotide , Lubiprostone , … …), by Market (Hospital Pharmacies , Retail Pharmacies , … …), by Company (Pfizer , Glaxosmithkline , … …)

Summary

The global Chronic Idiopathic Constipation Drugs market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
Linaclotide 
Lubiprostone 
Others
Demand Coverage (Market Size & Forecast, Consumer Distribution):
Hospital Pharmacies 
Retail Pharmacies 
Online Pharmacies
Company Coverage (Sales data, Main Products & Services etc.):
Pfizer 
Glaxosmithkline 
Roche Holding AG 
Sanofi 
Bayer AG 
Merck 
Eli Lilly 
Allergens 
Chugai Pharmaceutical 
Ferring International Center S.A 
Synergy Pharmaceuticals 
Salix Pharmaceuticals Ltd 
Sucampo Pharmaceuticals Inc 
Ironwood Pharmaceuticals Inc 
Valeant Pharmaceuticals International 
Daiichi Sankyo 
Cosmo Pharmaceuticals SA 
Progenics Pharmaceuticals Inc 
Theravance Biopharma Inc
Major Region Market
North America
Europe
Asia-Pacific
South America
Middle East & Africa
Table of Content
1 Industry Overview
1.1 Chronic Idiopathic Constipation Drugs Industry
1.1.1 Overview
1.1.2 Products of Major Companies
1.2 Market Segment
1.2.1 Industry Chain
1.2.2 Consumer Distribution
1.3 Price & Cost Overview
2 Chronic Idiopathic Constipation Drugs Market by Type
2.1 By Type
2.1.1 Linaclotide 
2.1.2 Lubiprostone 
2.1.3 Others
2.2 Market Size by Type
2.3 Market Forecast by Type
3 Global Market Demand
3.1 Segment Overview
3.1.1 Hospital Pharmacies 
3.1.2 Retail Pharmacies 
3.1.3 Online Pharmacies
3.2 Market Size by Demand
3.3 Market Forecast by Demand
4 Major Region Market
4.1 Global Market Overview
4.1.1 Market Size & Growth
4.1.2 Market Forecast
4.2 Major Region
4.2.1 Market Size & Growth
4.2.2 Market Forecast
5 Major Companies List
5.1 Pfizer  (Company Profile, Sales Data etc.)
5.2 Glaxosmithkline  (Company Profile, Sales Data etc.)
5.3 Roche Holding AG  (Company Profile, Sales Data etc.)
5.4 Sanofi  (Company Profile, Sales Data etc.)
5.5 Bayer AG  (Company Profile, Sales Data etc.)
5.6 Merck  (Company Profile, Sales Data etc.)
5.7 Eli Lilly  (Company Profile, Sales Data etc.)
5.8 Allergens  (Company Profile, Sales Data etc.)
5.9 Chugai Pharmaceutical  (Company Profile, Sales Data etc.)
5.10 Ferring International Center S.A  (Company Profile, Sales Data etc.)
5.11 Synergy Pharmaceuticals  (Company Profile, Sales Data etc.)
5.12 Salix Pharmaceuticals Ltd  (Company Profile, Sales Data etc.)
5.13 Sucampo Pharmaceuticals Inc  (Company Profile, Sales Data etc.)
5.14 Ironwood Pharmaceuticals Inc  (Company Profile, Sales Data etc.)
5.15 Valeant Pharmaceuticals International  (Company Profile, Sales Data etc.)
5.16 Daiichi Sankyo  (Company Profile, Sales Data etc.)
5.17 Cosmo Pharmaceuticals SA  (Company Profile, Sales Data etc.)
5.18 Progenics Pharmaceuticals Inc  (Company Profile, Sales Data etc.)
5.19 Theravance Biopharma Inc (Company Profile, Sales Data etc.)
6 Conclusion